Biotech VC Funds

Creadev, established in 2002 and supported by the Mulliez family, is a global evergreen investment firm dedicated to nurturing companies that have the potential to become industry leaders. With a presence in Paris, Shanghai, New York, and Nairobi, Creadev has built a diverse portfolio across healthcare, sustainable consumption, and food sectors. One of their notable investments is Twiga Foods, a prominent food distribution platform in Kenya that uses technology to streamline the supply chain between farmers and vendors, enhancing efficiency and sustainability. Another significant investment is Victory Farms, an East African aquaculture platform addressing nutritional security through sustainable fish farming solutions. Creadev has also backed Everytable, a U.S.-based food and beverage company committed to providing affordable and healthy meals to underserved communities. In the realm of plant-based foods, Creadev has invested in The Jackfruit Company, which produces meat substitutes using jackfruit, catering to the growing demand for sustainable and healthy food options. Additionally, they support Lifen, a French health tech company offering digital solutions to improve healthcare delivery and patient management. Creadev's investment approach emphasizes long-term commitment and aligns the investment horizon with the entrepreneurial vision. They often lead funding rounds and work collaboratively with other investors to support the growth and expansion of their portfolio companies. This strategy reflects their dedication to fostering sustainable and impactful businesses globally​.

Creandum is a leading European venture capital firm that specializes in early-stage investments, focusing on technology-driven companies within the consumer, software, and hardware industries. Founded in 2003, Creandum operates from its hubs in Stockholm, Berlin, London, and San Francisco, and is renowned for its thesis-driven approach to investing. The firm's notable portfolio includes high-profile companies such as Spotify, Klarna, Bolt, Depop, and Kahoot!. Creandum has also recently raised its seventh fund, a €500 million vehicle dedicated to supporting seed and early-stage startups across Europe. This fund aims to continue backing innovative companies poised to become global leaders. Creandum's investment philosophy emphasizes long-term commitment to founders, supporting them through the various stages of their growth journey. The firm prides itself on its deep industry expertise and extensive network, which it leverages to help startups scale and succeed in competitive markets. Recent investments include companies like Prewave, a supply chain disruption solution, and Plancraft, a platform digitizing work processes in the craft industry.

Creative Ventures is a venture capital firm focusing on market-driven deep technology investments. They invest in early-stage B2B companies that are commercializing novel scientific and engineering innovations. Key investment sectors include climate change adaptation and mitigation, healthcare, and addressing labor shortages in industrial and service sectors. The firm prides itself on a market-first approach, ensuring that the technologies they invest in are primed to meet existing market demand rather than speculative future needs. This strategy helps mitigate risks associated with deep tech investments​ (Creative Ventures)​​ (Creative Ventures)​. Creative Ventures has been a lead or co-lead investor in 80% of their investments from the current fund, often being the first institutional investor on a company's cap table​. Notable portfolio companies include Path Robotics, Sepion Technologies, and OncoPrecision, which focus on autonomous welding robots, advanced materials for energy storage, and oncology drug efficacy, respectively​. The team, led by General Partners Alex Luce and Kulika Weizman, brings extensive expertise in areas such as material science, synthetic biology, and biotechnology.

Creator Fund is a venture capital firm focused on backing scientific founders at the pre-seed and seed stages, primarily across the UK and Europe. Founded in 2019 by Jamie Macfarlane, the fund specializes in investing in deep technology and life sciences startups that emerge from university research. With a unique model, Creator Fund operates a network of PhD students across 25+ leading European universities, helping to identify promising ventures at the earliest stages of development. Creator Fund typically invests between £100,000 to £700,000 in early-stage startups, often backing companies where at least one founder is an academic—whether a professor, PhD, or recent graduate. They have built a diverse portfolio, including companies like Baseimmune (biotechnology) and Recycleye (AI-driven waste management). Their sector focus spans deep tech areas such as artificial intelligence, robotics, quantum computing, and biotech, aiming to support founders who are pioneering breakthroughs in their fields. Their investment strategy also emphasizes long-term involvement, often supporting founders through multiple funding rounds and connecting them with a strong network of co-investors across Europe and the U.S. The fund's leadership team, alongside Macfarlane, includes seasoned professionals who bring expertise from venture capital and deep-tech industries.

Crédit Mutuel Equity, the private equity arm of Crédit Mutuel Alliance Fédérale, focuses on supporting companies at various stages of their development, from early-stage growth to transformation and international expansion. Based in France, the firm has a diverse portfolio encompassing over 350 companies globally. Key investments include UroMems, which develops implantable mechatronics technology for medical applications; Quandela, a leader in quantum photonics; and HarfangLab, a cybersecurity company specializing in endpoint detection and response. Other notable companies in their portfolio are Latitude, a space launcher operator, and MentorShow, an EdTech SaaS platform. Crédit Mutuel Equity invests across multiple sectors, including healthcare, technology, consumer goods, energy, real estate, and logistics. They typically support companies with innovative business models and substantial growth potential, providing both financial investment and strategic guidance to help them scale and succeed.

Crosslink Capital, founded in 1989, is an early-stage venture capital firm based in Menlo Park and San Francisco. The firm focuses on investing in disruptive and market-transforming companies across enterprise and consumer technology sectors. As of April 2024, Crosslink closed its tenth flagship venture capital fund, Crosslink Ventures X, with $350 million in capital commitments, maintaining its focus on backing early-stage entrepreneurs from pre-seed through Series A stages​. A key component of Crosslink's strategy is the Alpha Network, an invite-only community of over 2,000 founders, CEOs, investors, and operators, established by General Partner Eric Chin in 2005. This network facilitates more than 40 annual events, including thematic discussions, networking parties, investor summits, and conferences, providing a rich ecosystem of support for founders. In conjunction with the recent fundraise, Crosslink has added Anduena Zhubi as the Director of Business Development, aimed at enhancing post-investment support for portfolio companies. Zhubi brings extensive industry experience from her previous roles at Microsoft and its venture arm, M12.

Crowberry Capital, a venture capital firm based in Reykjavik, Iceland, and Copenhagen, Denmark, focuses on seed and early-stage investments in the Nordic region. Founded by Helga Valfells, Hekla Arnardottir, and Jenny Ruth Hrafnsdottir, the firm aims to support innovative and high-potential startups across various sectors, including technology, digital health, and gaming. The firm has raised Iceland’s largest VC fund, a $90 million vehicle, which supports their mission to back diverse and bold entrepreneurs. Crowberry Capital’s portfolio includes notable companies such as Mainframe Industries, a gaming studio developing cloud-native social sandbox MMO Pax Dei; Lucinity, an AI-powered anti-money laundering platform; and Garden.io, which automates cloud development processes. Other investments include companies like Dreamdata, which focuses on B2B revenue attribution, and Kind, a provider of digital communication tools for healthcare providers​. Crowberry Capital prides itself on a strong follow-through philosophy, offering not only capital but also strategic support to help startups scale. Their approach has attracted significant interest from US VC funds at the Series A stage, highlighting the collaborative and robust nature of the Nordic startup ecosystem​.

CRV (formerly Charles River Ventures) is a well-established venture capital firm, founded in 1970, that focuses on early-stage investments in both enterprise and consumer technology startups. With over five decades of experience, CRV has supported the growth of more than 600 companies, including major successes like DoorDash, Airtable, Postman, and HubSpot. The firm is known for its hands-on approach and long-term commitment to helping founders build transformative companies. CRV typically leads investments and prides itself on moving quickly, often providing a term sheet within 24 hours. The firm aims to be a founder's first check, backing ambitious projects even in their earliest stages. They invest across various sectors, from enterprise software to consumer products, with notable focus areas like APIs (Postman), cloud networking (Aviatrix), and no-code solutions (Airtable). The firm’s investment ethos is built on forming deep, lasting partnerships with entrepreneurs, helping them navigate challenges and scale their businesses. CRV has offices in San Francisco and Palo Alto, California, with a team of partners experienced in working with startups through both good times and bad.

Crystal Horse Investments (CHI) is a Singapore-based venture capital firm with a focus on early-stage, angel, and seed investments. Established to support innovative startups across Southeast Asia, CHI has built a strong reputation for identifying high-potential companies, particularly in the technology, mobile, gaming, and web-based sectors. The firm actively participates in early funding rounds, including pre-seed, seed, and occasionally Series A, offering startups the critical capital and guidance they need to scale rapidly in competitive markets. Beyond just financial investment, CHI operates as an incubator, providing hands-on mentorship and strategic support to its portfolio companies. Startups benefit from Crystal Horse’s extensive network, industry insights, and operational expertise, allowing them to accelerate growth and navigate common early-stage challenges. The firm also collaborates with government initiatives such as Singapore’s iJam Reload program, which aims to nurture the next generation of tech innovators by providing incubation, mentorship, and early-stage funding opportunities. CHI has backed a diverse range of companies, from mobile app developers to cutting-edge web technology firms. With a strong belief in fostering innovation, CHI is committed to supporting entrepreneurs who are building the future of Southeast Asia’s digital economy. Their flexible investment approach, coupled with deep market knowledge, makes Crystal Horse a valuable partner for startups aiming to disrupt industries and scale regionally.

Cultivation Capital is a venture capital firm focused on early-stage investing, primarily at the Seed and Series A phases, with initial investments ranging from $100,000 to $3.5 million. Founded in 2012, the firm manages a family of funds targeting sectors such as life sciences and health tech, software and IT, agriculture and food tech, and geospatial technology. The firm has a mission to advance entrepreneurs with capital, counsel, and support while exceeding investors' expectations and creating opportunities for its team through career advancement and community impact. The firm operates several specialized funds, including partnerships with entities like the Yield Lab for Food and AgTech investments, and has backed over 120 startups. Notable investments include companies in diverse sectors such as therapeutics, diagnostics, precision agriculture, and location intelligence. Cultivation Capital is committed to building an inclusive portfolio, having invested in startups across more than 25 states and countries. The leadership team includes experienced venture capitalists and industry experts like co-founders Cliff Holekamp and Brian Matthews, as well as general partners and advisors with extensive backgrounds in their respective fields. The firm emphasizes active involvement with its portfolio companies, often taking board positions to provide strategic guidance and leverage their network of partners and investors.

Cultivian Sandbox Ventures is a venture capital firm dedicated to investing in innovative startups within the food and agriculture sectors. Founded in 2008 and headquartered in Chicago, the firm focuses on technologies that enhance crop production, animal health, food safety, and sustainability​. The firm has a robust portfolio featuring companies such as Vestaron, which is leading advancements in peptide-based crop protection, Supergut, offering functional food products for gut health, and Sound Agriculture, which develops products to help plants utilize soil nutrients more effectively​​. They also back companies like Geltor, which produces animal-free protein ingredients, and Full Harvest, a B2B marketplace for surplus produce​ (Cultivian Sandbox Ventures)​. Cultivian Sandbox Ventures recently closed its third fund at $135 million, with prominent investors including Archer Daniels Midland, Corteva Agriscience, and Ecolab. This fund focuses on Series A and B deals, with a global investment scope, looking particularly at synthetic biology, AI, and advanced materials​​. The team is led by experienced professionals like Andy Ziolkowski, who has over 30 years in venture capital and merchant banking, and Dan Phillips, who emphasizes the firm's commitment to platform technologies with multiple market applications​.

Cure Kids Ventures (CKV) is a seed and early-stage venture capital fund based in Auckland, New Zealand, established in 2008 as part of Cure Kids, a leading child health research charity. CKV invests in the commercialization of innovations that have the potential to improve child health globally. The fund focuses on healthcare-related sectors, including medical devices, biotechnology, diagnostics, medications, and health information systems. Its mission aligns closely with Cure Kids’ vision of a healthier future for children, supporting solutions that can make a significant impact on pediatric care​. CKV typically invests in pre-seed, seed, and Series A rounds, with initial investments ranging from under $500,000 to $3 million. The fund is highly selective, emphasizing strong commercialization potential. CKV has built an impressive portfolio, backing companies like the a2 Milk Company, Pictor, and The Clinician, which are making waves in health tech and biotech industries. Their investments are strategically aimed at driving innovations that address critical health challenges faced by children. The team at CKV brings global experience in biotechnology and healthcare, providing not only financial backing but also valuable insights into early-stage development and commercialization. CKV has played a crucial role in fostering the growth of New Zealand’s healthcare innovation ecosystem, and its impact extends beyond capital, as it works closely with startups to help them achieve market success.

Cure Ventures, based in Boston, Massachusetts, is a life sciences venture capital firm founded in 2021. The firm focuses on early-stage investments in biotechnology, particularly in new therapeutics. They aim to drive groundbreaking curative technologies from concept to clinical success. Cure Ventures closed their inaugural fund at $350 million, indicating substantial resources dedicated to their mission. The investment strategy at Cure Ventures emphasizes genetic validation to guide drug development, thus increasing the probability of success while reducing the cost of failure. They use a seed funding model to de-risk scientific ventures, with plans to co-lead Series A and B rounds for promising companies. Their hands-on approach involves embedding Cure operators within portfolio companies to assist with day-to-day decision making​. The team at Cure Ventures includes co-founders Richard Lim, David Fallace, and Lou Tartaglia, who bring extensive experience from successful biotech firms like Juno Therapeutics and Agios Therapeutics. Their backgrounds provide a strong foundation for supporting startups through scientific and operational challenges. Notable investments by Cure Ventures include Clasp Therapeutics, Kenai Therapeutics, and Tasca Therapeutics, reflecting their focus on innovative biotechnological solutions. Startups looking to approach Cure Ventures should highlight their potential for breakthrough therapies and be prepared for an intensive, collaborative partnership aimed at achieving significant medical advancements.

CyberAgent Capital (CAC) is a prominent venture capital firm specializing in early-stage investments, particularly in internet and technology-based startups. Founded in 2006 as part of the larger CyberAgent Group, the firm focuses on companies in the seed and early-growth stages. With a strong global network, CAC operates across key markets in Asia, including Japan, China, Taiwan, Indonesia, Vietnam, and Thailand, offering startups a bridge to regional and global expansion. The firm’s investment philosophy centers on incubating and accelerating internet-based businesses. CAC provides deep strategic and operational support, particularly in user acquisition, UI/UX design, and marketing strategies. This hands-on approach allows startups to leverage CAC’s extensive industry knowledge and its connection to the CyberAgent Group, fostering quicker growth in fast-moving markets​. CyberAgent Capital typically invests in startups aiming for global reach and scalability, helping them expand across borders. The firm manages several funds and offers flexible investment sizes depending on the growth stage, supporting companies from the initial idea phase to market expansion​. Some of CAC’s notable portfolio companies include Tokopedia, Coda Payments, and Viddsee, which highlight the firm’s successful track record in backing high-potential tech-driven ventures​.

Cybernetix Ventures is a venture capital firm focused on investing in early-stage robotics, automation, and artificial intelligence (AI) startups. Based in Boston, the firm invests globally, targeting companies that apply innovative automation technologies across various industries. Their portfolio includes cutting-edge startups such as Raise Robotics, which develops robots to improve safety and efficiency on construction sites, and Realtime Robotics, which creates processors for rapid, collision-free robot movements in unstructured environments. Cybernetix’s investment strategy focuses on companies in sectors like healthcare, industrial automation, and construction, aiming to revolutionize traditional industries through robotics and AI. Other notable portfolio companies include Kewazo, which offers robotic solutions to streamline construction processes, and Bionomous, which combines AI and micro-engineering to automate biological entity sorting, a breakthrough for healthcare labs. The firm is led by experienced partners like Mark Martin, who brings over 25 years of leadership in industrial and tech sectors. Cybernetix Ventures is known for its deep engagement with its portfolio companies, providing strategic support alongside capital to drive scalable growth in the rapidly evolving world of automation and robotics.

Cycle Capital, founded in 2009 and headquartered in Montreal, Quebec, is a venture capital firm that specializes in investing in early-stage cleantech companies. The firm aims to support businesses that are developing innovative technologies to create a sustainable future. Cycle Capital manages over CAD 600 million through various funds, targeting sectors such as renewable energy, smart grid technology, energy storage, green chemicals, and advanced materials. The firm's portfolio includes a wide range of companies focused on sustainable innovations. Notable investments include Rhombus Energy Solutions, which develops bi-directional electric vehicle charging infrastructure; Bus.com, an online bus reservation platform; and Airex Energy, which transforms biomass into biochar and biocoal. Other significant investments are in GreenMantra Technologies, which converts waste plastics into specialty polymer additives, and Mysa, which creates smart thermostats for electric HVAC systems. Cycle Capital has also achieved several successful exits, including the acquisition of Rhombus Energy Solutions by BorgWarner in 2022. This acquisition was a significant milestone, showcasing the firm's ability to scale innovative companies to global markets. The firm is led by founder and managing partner Andrée-Lise Méthot, along with a team of experienced partners and venture capitalists. They emphasize long-term collaboration with entrepreneurs, providing both financial support and strategic guidance to help their portfolio companies achieve significant growth and impact.

DAAL Ventures is a venture capital firm headquartered in Saudi Arabia, focusing on early-stage investments in the technology sector, particularly in emerging markets. Founded with the mission to bridge international innovation and the Middle East, DAAL plays a pivotal role in helping startups expand into the GCC region, especially Saudi Arabia. The firm is known for providing not only capital but also strategic guidance and mentorship to its portfolio companies. DAAL leverages its extensive regional network and expertise to support startups in various sectors, including fintech, SaaS, artificial intelligence (AI), Internet of Things (IoT), and big data. DAAL Ventures stands out for its collaborative approach, positioning itself as a partner to the companies it backs. This involves helping entrepreneurs scale their operations globally and connecting them with world-class investors and local partners in the Middle East. The firm has invested in a diverse range of startups, including Pulppo, a Mexican proptech platform, and Paym.es, a fintech company, highlighting its commitment to identifying high-potential tech ventures across different regions​. The firm’s vision is to be a leader in tech-focused venture capital in Saudi Arabia and the broader GCC region. DAAL is committed to fostering growth by offering operational support, business development resources, and access to its network of strategic partners. This positions DAAL Ventures as a key player for startups looking to break into the Middle Eastern market​.

Danone Ventures, the corporate venture arm of Danone, is at the forefront of investing in groundbreaking startups within the food and beverage industry. Notable investments include Farmer's Fridge, Harmless Harvest, and Michel et Augustin, demonstrating their commitment to supporting innovative brands that push the boundaries of health and sustainability. With a strategic focus on early-stage companies, Danone Ventures targets sectors such as plant-based products, sustainable food systems, and personalized nutrition. Their geographic reach spans across North America, Europe, and increasingly into emerging markets, showcasing a global outlook with a local touch. Danone Ventures employs a proactive investment strategy, often taking significant stakes and leading funding rounds. They typically invest between $1M and $10M, providing not just capital but also leveraging Danone's extensive resources to help startups scale. The firm has shown consistent activity, with recent investments in companies like Nature’s Fynd and Ready, Set, Food!, highlighting their commitment to innovation and sustainability. The team at Danone Ventures includes experts like Laurent Marcel and Emmanuel Faber, who bring deep industry knowledge and a passion for transforming the food landscape. Startups looking to partner with Danone Ventures should emphasize their innovative approach and alignment with Danone's mission of bringing health through food to as many people as possible. Being approachable and showcasing strong market potential are key to gaining their interest. Danone Ventures is dedicated to fostering a healthier world through strategic and impactful investments.

Daphni Ventures, based in Paris, was founded in 2016 and focuses on early-stage investments with a European DNA and strong international ambition. The firm aims to support companies that contribute to making the world a better place through innovative and disruptive models, emphasizing social and environmental sustainability. Daphni's investment thesis revolves around empowering founders to create a sustainable future by leveraging deep tech and innovation. The firm has made over 80 investments and has seen multiple successful exits, including Shine.fr, Masteos, and Foxintelligence. Their portfolio includes a wide range of companies such as ZOE, a personalized nutrition platform; Double, a remote executive assistant service; and Masteos, a full-stack real estate agency. They also back companies in sectors like edtech, fintech, and health tech, supporting ventures that focus on the circular economy, upcycling, social inclusion, and the future of work. Daphni operates three main investment vehicles: Purple, Yellow, and Dastore, each focusing on different areas of innovation and sustainability. Their approach involves not only providing capital but also offering operational support and access to a community of experts to facilitate collaboration and knowledge-sharing among their portfolio companies.

DarkMode Ventures is an early-stage venture capital firm founded in 2021 by Amir Shevat, Kat Orekhova, and Rapha Danilo, all of whom are seasoned entrepreneurs with deep experience in developer platforms, AI, and enterprise software. With a fund size of $5 million, DarkMode specializes in writing checks between $100,000 and $200,000, focusing on startups in the developer tools, AI/ML, and modern data stack sectors. Notable investments include Drata, Tabnine, Merge, and Bluesky, with the fund targeting both U.S.-based and international companies, particularly in Israel. DarkMode prides itself on a “by builders for builders” ethos, where they leverage their operational expertise to provide hands-on support to founders. They aim to be more than just a financial backer, offering real-world advice and maintaining a close, transparent relationship with startups. The firm typically does not lead funding rounds but collaborates with other VCs and strategic angels to help startups secure their first significant investments. Their LPs include executives from major tech companies like Meta, Google, and Coinbase, as well as leading institutional investors like Bain Capital and Foundation Capital. DarkMode is known for its fast decision-making process and commitment to founders with a clear vision and strong execution skills. Their focus is on building long-term relationships and backing founders willing to take big risks for transformative outcomes​.

Day One Capital, founded in 2011, is a venture capital firm based in Budapest, Hungary, focusing on early-stage technology startups primarily in the Central and Eastern European (CEE) region. They are known for their investments in B2B software companies, leveraging the region's strong talent pool to support technology-driven founders. Day One Capital has built a diverse portfolio across various industries, including AI, fintech, and logistics. Notable investments include Turbine AI, which uses simulated cell technology to enhance drug discovery; Webshippy, a logistics and fulfillment service provider; and Volteum, a company aiding electric vehicle fleet management. They have also backed companies like Colossyan, which specializes in generative AI for video editing, and Commsignia, a leader in automotive IoT​. Their typical investment range is from €300k to €1.5 million for seed and Series A rounds. They have been instrumental in helping companies scale globally, providing not only capital but also strategic support and mentorship from their experienced team, which includes former government officials and seasoned investors​​. Day One Capital continues to foster growth and innovation within the CEE region, contributing significantly to the local startup ecosystem and helping companies achieve successful exits, such as AImotive's acquisition by Stellantis and NOW Technologies' acquisition by Sunrise Medical​​.

Day One Ventures, founded by Masha Bucher in 2018, is a dynamic early-stage venture capital firm based in San Francisco. Known for their unique approach, they combine investment with hands-on PR and communication support, setting them apart in the VC landscape. The fund focuses on industries such as fintech, climate and energy, AI, deep tech, consumer products, and enterprise solutions, with a geographic emphasis on North America and Europe. Their portfolio boasts notable investments in companies like DuckDuckGo, Remote, WorldCoin, and Superplastic. Day One Ventures typically invests between $100K and $1M, often leading seed and Series A rounds. They have a strong track record, with 22 exits and several unicorns under their belt, aggregating over $115 billion in value. Masha Bucher, a Forbes 30 Under 30 honoree and former PR executive, leverages her extensive communications background to provide unparalleled support to portfolio companies, from media strategy to investor introductions. The team, including key members like Drake Rehfeld and Tara Harandi-Zadeh, is deeply involved in every step of the startups' journeys, fostering a close-knit community.

DBL Partners, also known as DBL Investors, is a pioneering venture capital firm that integrates financial returns with social, environmental, and economic benefits—a concept they refer to as the "Double Bottom Line." Founded in 2004 and based in San Francisco, DBL Partners has a strong portfolio that includes high-profile companies such as Tesla, SpaceX, SolarCity, and Pandora. Their investments span sectors like clean energy, sustainable products and services, information technology, and healthcare. DBL's investment strategy is rooted in the belief that strong financial performance and positive social impact are interconnected. This approach is evident in their support for companies like Revolution Foods, which provides healthy meals to schools, and Ecologic Brands, which produces environmentally friendly packaging. DBL assists its portfolio companies not only with capital but also by helping them achieve secondary social and environmental goals, such as creating jobs in underserved communities or reducing carbon footprints. Key team members include Nancy Pfund, who has been instrumental in shaping DBL's impact investment strategy. DBL's focus on nurturing the social aspects of their investments has led to successful outcomes, both in terms of market traction and community benefits. For instance, Pandora's decision to locate its headquarters in Oakland helped revitalize the area and create jobs.

DCM Ventures, founded in 1996 and based in Menlo Park, California, is a prominent venture capital firm known for its extensive portfolio and successful investments. With over $4 billion under management, DCM focuses on early-stage technology companies across the U.S., China, and Japan. Notable investments by DCM Ventures include companies like SoFi, Careem, Fortinet, and Matterport. These companies highlight DCM’s diverse investment strategy, spanning fintech, cybersecurity, consumer internet, and enterprise software. The firm has also backed companies like Bill.com and Musical.ly (now TikTok), which have seen significant growth and success​​. DCM Ventures operates with a global perspective, investing in the three largest technology markets: the U.S., China, and Japan. This strategic approach has enabled DCM to deliver strong returns to its limited partners, with a focus on early-stage SaaS, fintech startups, and consumer internet companies. The firm has seen numerous successful exits, with 254 companies in its portfolio going public or being acquired​​. The leadership team at DCM includes co-founders David Chao and Xinhe Lin, who guide the firm’s global investment strategy and operational support to its portfolio companies. For startups looking to connect with DCM Ventures, demonstrating innovative solutions in high-growth sectors such as fintech, AI, and cybersecurity can align well with the firm’s investment focus​.

DCVC (Data Collective Venture Capital) is a deep tech venture capital firm based in Palo Alto, California, founded in 2010 by Matthew Ocko and Michael Driscoll. The firm focuses on investing in groundbreaking technologies that address significant global challenges across various sectors, including artificial intelligence, space, climate, engineering, and more. DCVC manages multiple funds, including DCVC V, which is a $725 million fund aimed at disrupting substantial sectors of the global economy. The firm emphasizes backing startups that employ computational and engineering approaches to solve high-stakes problems. Notable portfolio companies include Pivot Bio, Planet, Zymergen, Atomwise, Rocket Lab, and Recursion Pharmaceuticals, all of which are leaders in their respective industries. DCVC also has a specialized branch, DCVC Bio, co-founded with Dr. John Hamer and Dr. Kiersten Stead, focusing on AI-enabled life sciences platforms. This branch aims to bring new medicines to market and commercialize biological breakthroughs, with companies like AbCellera, Chroma Medicine, and Totus Medicines leading the charge​. The firm’s investment strategy is driven by a belief that venture capital can address urgent global problems profitably and equitably, turning challenges into opportunities while delivering strong returns. DCVC continues to expand its team with experts across various fields to support its growing portfolio and mission​.

Decent Capital, founded in 2007 by Jason Zeng, co-founder of Tencent, is a prominent venture capital firm with a global presence. The firm focuses on early-stage investments across sectors such as SaaS, consumer internet, frontier tech, and sustainable technology, with investments ranging from pre-seed to Series A stages. Decent Capital’s diverse portfolio includes notable companies like Lime, Cider, and Huizuche. Lime is well-known for its smart scooters and bikes aimed at addressing last-mile transportation issues, while Cider is a direct-to-consumer e-commerce platform for fashion. Huizuche, another significant investment, focuses on car rental services in China. The firm has seen successful exits, such as the acquisition of Oculii and Huizuche, and the IPO of FangDD on NASDAQ in 2019. The firm’s investment strategy emphasizes supporting companies through their growth stages with continued capital and strategic guidance. Decent Capital operates from multiple locations, including offices in Shenzhen, Hong Kong, Singapore, and the United States, ensuring a broad reach and impact across various markets.

Deep Science Ventures (DSV) is a London-based venture studio founded in 2016 that specializes in building science-driven startups across four key sectors: agriculture, computation, climate, and pharmaceuticals. DSV's approach is unique in that it combines scientific knowledge with entrepreneurial expertise to create high-impact ventures from scratch. They partner closely with founder-scientists to tackle some of the world's most pressing challenges, such as reversing global warming, developing curative therapeutics, and advancing computational technologies. DSV's portfolio includes a diverse range of companies, such as Mission Zero Technologies, which focuses on energy-efficient direct air capture of CO2, and Neobe Therapeutics, which is engineering bacteria to improve the efficacy of cancer immunotherapy. These ventures reflect DSV's commitment to creating transformative solutions that are both scientifically rigorous and commercially viable. The firm's model emphasizes de-risking ventures through deep technical and market analysis before significant capital is committed. This methodical approach ensures that the startups they create have a strong foundation for long-term success.

Deepbridge Capital, established in 2010 and headquartered in Chester, UK, focuses on providing growth capital to companies in the technology, life sciences, and renewable energy sectors. Their investment approach emphasizes supporting innovative and high-growth potential companies through various tax-efficient investment opportunities. Deepbridge Capital's portfolio includes a diverse array of companies. Notable investments are in firms like AlgaeCytes, which specializes in producing high-quality EPA oils from algae, and VoxSmart, which provides compliance management solutions for banks. They have also invested in promising startups like Thalia Design Automation, an AI-driven EDA platform, and Ibis Vision, a cloud-based vision testing software for the optical industry. The firm has made 168 investments and has seen 101 exits, showcasing their experience and success in nurturing companies to achieve significant milestones. Deepbridge Capital also supports companies through initiatives such as the Deepbridge Technology Growth EIS Fund and the Deepbridge Innovation SEIS Fund, offering financial backing and strategic guidance to early-stage businesses. The Deepbridge team, led by Managing Partner Ian Warwick, is known for their commitment to fostering innovation and growth across their investment sectors. For more information about their investments and strategic approach, you can visit their official website.

The DeepTech & Climate Fonds (DTCF) is a German venture capital fund aimed at supporting growth-stage startups working on transformative technologies in sectors such as deep tech and climate tech. Established in 2023, the fund has a capital pool of €1 billion, sourced from Germany’s Future Fund and the European Recovery Program. It focuses on companies developing solutions in fields like Industry 4.0, quantum computing, AI, and clean energy technologies. DTCF primarily invests in companies that require long development cycles and substantial capital, providing them with the resources to scale their innovations across Europe. The fund works as an anchor investor, partnering with institutional investors, family offices, and private capital to ensure that these companies can achieve commercial success and contribute to a climate-neutral economy. Led by Dr. Elisabeth Schrey and Tobias Faupel, DTCF has already made notable investments in companies like Membion, which focuses on wastewater recycling, and Cylib, a battery recycling startup. The fund's mission is to drive systemic change by investing in technologies that will reshape industries and contribute to sustainability across the European tech landscape​.

DeepWork Capital, established in 2015 and based in Orlando, Florida, is an early-stage venture capital firm. The firm primarily targets technology and life sciences startups, particularly those in U.S. regions traditionally underserved by venture capital. DeepWork Capital's investment strategy focuses on seed and Series A stage companies, often being the first institutional capital after friends, family, and angel investors. Their portfolio includes a diverse range of companies such as AbFero Pharmaceuticals, acquired by Pharmacosmos, and AireHealth, addressing respiratory challenges. Other notable investments include Astrocyte Pharmaceuticals, developing therapeutics for brain injury, and Genascence, working on gene therapy for musculoskeletal diseases. The firm also supports innovative startups like Nanophotonica, which is pioneering EL-QLED technology, and Homee, which digitizes insurance claims processes. The DeepWork Capital team, including Managing Partners Mitchel Laskey, Ben Patz, and Kathy Chiu, brings a wealth of experience from various industries. The firm emphasizes a hands-on, active engagement approach, supporting entrepreneurs before, during, and after investment. DeepWork Capital's mission is to foster innovation in regions like Florida by providing necessary capital and strategic support to tech-forward founders committed to solving significant societal challenges.

Deerfield Management, a prominent investment firm based in New York City, is dedicated to advancing healthcare through strategic investments, information, and philanthropy. With over $14.6 billion in assets under management, Deerfield maintains a diverse portfolio of more than 200 private and public investments across biotechnology, pharmaceuticals, medical devices, healthcare services, and digital health industries​ . Notable portfolio companies include Graphcore, JFrog, and Netskope. The firm has a strong track record of supporting startups from early stages to mature companies, offering flexible funding models, including equity, debt, and joint ventures. Deerfield’s investment approach is characterized by deep operational support and a robust network of strategic partners and academic collaborations​ ​. Deerfield’s team comprises over 150 experienced professionals with expertise in various sectors of healthcare and finance, ensuring comprehensive support for their portfolio companies. The firm’s initiatives, such as the Deerfield Discovery and Development (3DC) and the Cure Campus, further highlight their commitment to fostering innovation and addressing complex health issues​​. The Deerfield Foundation, part of the firm’s philanthropic efforts, focuses on improving healthcare delivery, particularly for underserved populations, and has invested over $68 million in various health initiatives.

Define Ventures is a premier early-stage venture capital firm, singularly focused on investing in digital health companies. With a keen eye for transformative potential, Define Ventures partners with innovative entrepreneurs to reshape the healthcare landscape. Their portfolio features notable investments such as Blackbird Health, which is revolutionizing pediatric mental health, and Lightship, a pioneer in decentralized clinical trials. Define Ventures operates primarily within the digital health sector, focusing on business models that integrate technology and healthcare to create scalable solutions. Geographically, they concentrate their efforts within the United States, fostering close relationships with startups that promise substantial impact in the national healthcare system. The firm’s strategy centers on leading early-stage funding rounds, including incubation, seed, Series A, and Series B stages. Define Ventures is renowned for their hands-on approach, providing not just capital but also strategic guidance and industry expertise to help their portfolio companies thrive. The team is led by industry veterans like Lynne Chou O'Keefe, the founder and managing partner, whose vision drives the firm's success. Other key members include A.G. Breitenstein and Frank Williams, both of whom bring extensive experience in healthcare and digital innovation. Define Ventures has recently closed $460 million across Fund III and an Opportunities Fund, cementing its position as a significant player in digital health investment.

Defy Ventures, a New York-based venture capital firm founded in 2010 by Catherine Hoke, focuses on early-stage investments and supporting entrepreneurs, particularly those with unconventional backgrounds such as former convicts. The firm is dedicated to fostering entrepreneurship, employment, and character training for its community. Defy's portfolio includes notable companies such as Nautilus Biotechnology, Empower, and Shujinko. They have made significant investments in various sectors, including high tech, business services, and food and agriculture tech. Recent investments include Monitaur, Writ, and Delivery Collective. The firm values authenticity and the tenacity needed to transform bold ideas into lasting companies. Defy Ventures aims to be the partner of choice for today's daring startup founders, helping them become tomorrow's visionary leaders. They emphasize working behind the scenes to amplify the success of their portfolio companies.

Delin Ventures is a UK-based, mission-driven venture capital firm that focuses on early-stage investments, specializing in two key areas: Life Sciences and the Future of Work & Learning. Established in 2015, the firm backs founders working on breakthrough technologies that can transform healthcare through cell therapies and the future of human work and learning. Delin invests in pre-seed and seed rounds, with typical ticket sizes ranging from €100,000 to €1.5 million, primarily in European startups. In the Life Sciences domain, Delin is committed to advancing cell therapy solutions that can either cure life-threatening diseases or transform them into manageable, chronic conditions. They also invest in the infrastructure necessary for the development and commercialization of these therapies. Notable investments include startups working on innovative therapeutics, medical services, and manufacturing technologies. In the Future of Work & Learning sector, Delin Ventures aims to unlock human potential by investing in technologies that shape the workforce of tomorrow. This includes HR tech, productivity tools, workforce development, and upskilling platforms. They provide hands-on support to founders, leveraging their deep operational expertise and extensive network. The team, led by founder Igor Linshits, includes experts from various industries, ensuring a strong focus on long-term impact. Delin's strategy is centered around making fewer, high-quality investments to ensure that they can offer exceptional support to their portfolio companies, which includes businesses like Fluidic Analytics, Vidsy, and Ori Biotech. The firm is highly selective, providing patient capital and working closely with founders to scale impactful solutions.

Dell Technologies Capital (DTC) is the venture capital investment arm of Dell Technologies, focusing on early-stage investments in the enterprise technology space. Since its inception in 2012, DTC has invested in over 150 companies, helping to propel innovations in data and analytics, cybersecurity, infrastructure, developer tools, and silicon. Their notable portfolio includes industry leaders like DocuSign, MongoDB, and Cylance​. DTC’s investment strategy is to partner with founders from the early stages and provide not only capital but also deep domain expertise and operational support. The firm’s extensive network within Dell Technologies offers startups real customer connections and the opportunity to scale with the backing of a tech giant. Investments typically range from seed to growth stages, with DTC often leading the rounds​. Headquartered in Palo Alto, California, DTC’s team of investors, technologists, and operators work closely with portfolio companies, guiding them from inception to market leadership. This hands-on approach ensures that the startups benefit from strategic insights and operational know-how, positioning them for successful exits​​. Overall, Dell Technologies Capital stands out for its commitment to fostering groundbreaking enterprise technologies and its robust support system for startups aiming to disrupt the tech landscape.

Delphi Ventures, founded in 1988, is a venture capital firm based in San Mateo, California. The firm focuses primarily on life sciences, including biotechnology, medical devices, and healthcare IT. Over the years, Delphi Ventures has made significant contributions to the life sciences industry with over 318 investments and 190 exits. Notable investments by Delphi Ventures include Revance Therapeutics, Senseonics, and PTC Therapeutics. These companies have developed innovative solutions in neurotoxin aesthetics, continuous glucose monitoring, and treatments for rare diseases, respectively. Revance Therapeutics, for instance, is now a public company with significant revenue, reflecting Delphi Ventures' ability to identify and nurture high-potential startups. Delphi Ventures' investment strategy is centered on early and growth-stage investments, with a focus on supporting pioneering technologies and therapies. The firm has a strong track record of successful exits, including companies that have gone public such as EBR Systems and Senseonics, as well as several notable acquisitions like Seattle Genetics and Acclarent. The team at Delphi Ventures is led by experienced professionals such as Deepa Pakianathan, Douglas Roeder, and founder James Bochnowski. Their expertise and deep industry knowledge play a critical role in guiding portfolio companies toward successful growth and market leadership.

Demeter, a major European player in venture capital, private equity, and infrastructure, focuses on investments that drive the energy and ecological transition. Founded in 2005, Demeter manages €1.3 billion across its funds and has completed over 230 investments. The firm targets innovative startups, SMEs, and infrastructure projects, offering investments ranging from €1 million to €30 million. Notable investments include McPhy Energy, which specializes in hydrogen production, storage, and distribution technologies, and Ynsect, which produces environmentally friendly insect-based products. Demeter also supports companies like Sunna Design, which develops solar LED lighting solutions, and Sweetch Energy, a renewable energy firm focusing on osmotic energy. One of Demeter's significant initiatives is the recent launch of a €500 million fund in collaboration with EIT InnoEnergy. This fund aims to develop a resilient and diverse battery raw material supply chain for Europe, addressing the continent's growing demand for batteries and supporting the European Battery Alliance's goals. Demeter's investment strategy is driven by a commitment to sustainability, evident in their support for green projects like H2 Green Steel, the world's first integrated large-scale green steel plant. The firm's dedication to environmental responsibility is further reflected in their involvement in initiatives like the Climate Dividends program, which promotes sustainability across their portfolio companies.

Derayah Ventures is a Saudi-based venture capital firm that invests in early to growth-stage startups across the MENA region. Launched in 2019, the firm manages a $30 million fund focused on technology-driven businesses, particularly in sectors such as SaaS, fintech, eCommerce, artificial intelligence, Internet of Things (IoT), and marketplace platforms. Derayah primarily backs companies that are either disrupting traditional industries or organizing them through innovative solutions. The firm’s investment philosophy centers on supporting scalable startups with high growth potential and strong teams. Derayah Venture Capital provides not just financial backing but also strategic guidance to help companies expand within the MENA region, especially into Saudi Arabia. The fund focuses on post-seed, pre-Series A, and Series A stages, enabling startups to access critical capital during their early development phases. Led by a team of experienced investors, including Chairman Faris Ibrahim AlRashed, Derayah aims to build tomorrow's market leaders through a combination of capital, industry expertise, and strong local networks.

Detroit Venture Partners (DVP), founded in 2010 by Dan Gilbert, is a venture capital firm committed to backing early-stage tech startups that aim to drive innovation and economic growth. Based in Detroit, DVP is part of the broader Rock Family of Companies, which includes Rocket Companies, Bedrock Detroit, and the Cleveland Cavaliers. This extensive network enables DVP to offer its portfolio companies not only financial backing but also strategic partnerships and resources to help them scale effectively. DVP focuses on investing in startups that embody creativity, grit, and passion. They have a strong emphasis on companies in the technology sector, including fintech, SaaS, and logistics. Some of their notable portfolio companies include StockX, Livegistics, 100 Thieves, and CoverTree. By fostering innovation, DVP contributes to Detroit’s entrepreneurial ecosystem, helping to rejuvenate the city’s long history of industrial innovation. In addition to their investment activities, DVP runs a Summer Fellowship program that offers MBA and undergraduate students hands-on experience in venture capital and early-stage startups.

Dexcel Pharma is the largest private pharmaceutical company in Israel, renowned for its extensive portfolio of branded and generic drugs. Founded in 1968, the company has grown into a global player, with state-of-the-art R&D and manufacturing facilities that support the development and commercialization of innovative and cost-effective pharmaceutical products. Dexcel's product portfolio spans across various therapeutic areas, including small molecules, biologics, and RNA-based therapies. The company is committed to advancing science through substantial investments in R&D, particularly in cutting-edge fields like siRNA therapeutics and oligonucleotides. Their innovation initiatives include the creation of specialized entities like Dexoligo Therapeutics, which focuses on RNA-based medicines, and Clexio Biosciences, which develops treatments for neurological and psychiatric conditions. With over 1,200 employees and a strong presence in key markets like the United States, Germany, and the UK, Dexcel manufactures over 5 billion oral-solid dosages annually. The company maintains a reputation for quality, with its facilities meeting global standards and holding approvals from regulatory bodies like the FDA and EMA.

DG Daiwa Ventures, a Tokyo-based venture capital firm founded in 2016, is a joint venture between Digital Garage and Daiwa Securities Group. The fund focuses on early-stage investments in cutting-edge technologies, such as blockchain, artificial intelligence (AI), cybersecurity, biohealth, and extended reality (xR). DG Daiwa Ventures operates globally, with a special emphasis on startups in Japan and the broader Asia-Pacific region. The firm manages two main funds: DG Lab Fund I and DG Lab Fund II, which collectively manage over 20 billion yen. These funds target high-potential tech startups by leveraging the combined expertise and incubation capabilities of both Digital Garage and Daiwa Securities. DG Daiwa Ventures has a track record of nurturing successful startups, such as Goodpatch and Akili Interactive Labs, which have gained recognition for their innovative products. DG Daiwa is known for supporting its portfolio companies with strategic resources and helping them scale through partnerships, additional fundraising, and IPO support. The firm aims to identify companies that can drive technological advancements and create substantial returns for investors through a global network of partners and later-stage investors.

DHVC, founded in 2013 by Shoucheng Zhang, is a venture capital firm based in Palo Alto, California. The firm focuses on early-stage investments across several sectors, including enterprise, consumer, fintech, and healthcare. Over the years, DHVC has built a substantial portfolio, investing in over 267 companies with 75 successful exits​. DHVC has also seen significant exits with companies like Wish Shopping, Qeexo, and Namocell, indicating their strong presence in the tech investment space. The firm’s investment strategy involves participating in a mix of seed, early-stage, and later-stage funding rounds, often co-investing with other prominent venture capital firms​. The DHVC team, led by key members such as Kevin Ding and Judy Yan, brings a wealth of experience and a global perspective to their investment approach. The firm’s operations are split between the United States and China, allowing them to leverage opportunities across major innovation hubs​.

Diamond Capital is a venture capital firm based in Taiwan, primarily focusing on investments in the biotechnology, medical, and high-tech sectors. Established in 2013, the firm has built a strong reputation for nurturing innovative companies that are driving advancements in healthcare, new drug development, high-end medical equipment, and innovative medical services. Diamond Capital is known for its strategic investments that span early to growth-stage companies, particularly those operating in Asia. The firm is particularly noted for its involvement in the biotechnology sector, where it has been instrumental in supporting startups that have gone on to achieve significant milestones, including public listings. Diamond Capital's strategy involves not only providing capital but also leveraging its extensive network and expertise to guide companies through the complexities of scaling and entering global markets. This approach has made it a key player in Taiwan’s venture capital landscape. In 2023, Diamond Capital made headlines by becoming the first biotech venture capital firm to list on the Taiwan Stock Exchange, further enhancing its visibility and credibility on the international stage. The firm's portfolio includes a diverse array of companies, from cutting-edge biotech firms to innovative medical device manufacturers, all of which are united by their potential to make significant contributions to their respective fields.

DIC Corporation operates a Corporate Venture Capital (CVC) unit that focuses on strategic investments aligned with their core mission of sustainable innovation. Founded as a global leader in fine chemicals, DIC leverages its venture capital arm to support startups that bring new, disruptive technologies in areas like biomanufacturing, advanced materials, and industrial IT. Their investment strategy aims to complement their existing businesses in sectors such as color science, healthcare, and packaging. Recent notable investments include funding Debut Biotechnology, a California-based company specializing in sustainable biomanufacturing. This partnership allows DIC to accelerate the development of bio-based materials, particularly natural pigments for cosmetics and nutrition, aligning with their long-term vision of sustainability under the DIC Vision 2030 plan. DIC's CVC activities also extend to partnerships with other venture funds, such as their collaboration with Emerald Technology Ventures, which focuses on industrial innovation in clean technology. DIC’s strategic approach to venture investing helps them explore new markets while enhancing their capabilities in sustainable products, driving innovation across their global network of over 190 companies.

DCP Capital is a private equity firm based in Beijing, China, founded in 2017 by Julian Wolhardt and David Liu. The firm focuses on investments in companies operating in sectors such as healthcare devices, semiconductors, commercial services, agriculture, and manufacturing across Mainland China, Hong Kong, Macau, and Taiwan. Notable investments by DCP Capital include Jamieson Wellness, a leading consumer health brand; Mengniu Dairy, one of China’s largest dairy producers; and 51job, a major recruitment website in China, which was acquired for $3.8 billion. The firm has also invested in innovative companies like Broncus Medical, Venus MedTech, and Fenbi, which focuses on education and training services. DCP Capital manages assets of over $2.5 billion, having recently completed the first close of their second China fund. This fund aims to invest in early and growth-stage companies, furthering their mission to support transformative businesses in the region.

Digitalis Ventures is a venture capital firm established in 2016, focused on investing in innovative solutions within the realms of human and animal health. Headquartered in New York, with offices in Boston, Los Angeles, San Diego, San Francisco, and Gainesville, the firm leverages deep technical, financial, and domain expertise to support early-stage companies. Digitalis Ventures’ portfolio includes companies like Expressable, Elegen, and Alterome Therapeutics, reflecting their interest in biotechnology, health technologies, and services. Notable exits include Scout Bio and PetMedix. The firm typically leads investment rounds, providing substantial capital and strategic guidance to help startups scale. The investment strategy centers around life sciences, health technologies, and animal health. They invest in companies developing breakthrough technologies in therapeutics, diagnostics, and tools that improve healthcare access, outcomes, and efficiency. Their Companion Fund specifically focuses on advancing animal health. Key team members include founder Geoffrey Smith and partners such as Amit Bansal and Drew Taylor, who bring extensive experience in venture investing and health technologies.

firm focuses on investing in early-stage companies within the digital health sector, aiming to address significant challenges and inefficiencies in healthcare. Their investment strategy centers on data-driven technologies that can revolutionize healthcare and improve patient outcomes through innovative solutions in personalized medicine, data analytics, and digital therapeutics. DigiTx Partners is notable for backing companies like Eko, which develops diagnostic devices for heart and lung diseases, and Rune Labs, which focuses on precision neurology through software and data analytics. Their portfolio also includes Cleerly, specializing in cardiovascular disease diagnostics, and Savonix, which offers cognitive function management systems. The firm was created as a joint venture between Astellas Pharma and MPM Capital, and it raised $75 million for its Rx Digital Fund in 2018. This fund supports seed and Series A-stage companies that are developing healthcare and life sciences technology utilizing data​. Key team members include Managing Director David Kim, MD, and Partner & Principal Miraj Sanghvi, who bring substantial expertise in healthcare and investment management.

Dimension Capital is an early-stage venture capital firm founded in 2022 by industry veterans from Lux Capital and Obvious Ventures. With a focus on the intersection of biotechnology, life sciences, and technology, the firm operates a $350 million fund aimed at digitizing the biotech sector. Their mission is to break down the traditional silos separating technology and life sciences, creating new synergies between fields like drug discovery and artificial intelligence. Dimension invests in startups that leverage technology to drive advancements in biotech, such as Enveda Biosciences and Kaleidoscope Bio. The firm targets transformative companies in sectors including AI-driven drug discovery, machine learning applications in healthcare, and advanced manufacturing. Led by Adam Goulburn, Zavain Dar, and Nan Li, Dimension emphasizes long-term partnerships with founders, providing both capital and strategic guidance. They are particularly interested in companies at the forefront of merging biology with computational technologies, a space they believe is critical to the future of medicine​. Based in New York and San Francisco, Dimension is well-positioned in two key innovation hubs, giving it access to cutting-edge talent and startups that are redefining the biotech landscape​.

Divergent Capital is a New York-based venture capital firm founded in 2020 by Katie Shea and Lucy Wang. The fund focuses on pre-seed investments, typically writing checks between $250,000 and $750,000. Divergent Capital aims to back 20-25 companies, emphasizing high-conviction investments with deep engagement in sectors like AI, machine learning, robotics, biotech, logistics, and digital health. The firm is known for investing in founders with innovative technologies and unique customer insights, often those outside the traditional Silicon Valley circles. Divergent takes a hands-on approach with its portfolio companies, offering strategic guidance on product development, go-to-market strategies, and scaling. They prefer working with founders who have a deep personal connection to the problem they are solving, focusing on practical, product-driven growth rather than market size alone. Notable investments include companies like Hoop, Motif Neurotech, and Ceragen, spanning industries from productivity software to biotechnology.

DN Capital, founded in 2000, is a global early-stage venture capital firm with offices in London, Berlin, and San Francisco. They focus on Seed, Series A, and select Series B opportunities across Europe and North America. The firm specializes in sectors such as fintech, SaaS, digital media, marketplaces, and consumer internet. Some of DN Capital's notable investments include Shazam, Auto1, OLX, Purplebricks, and GoStudent. These investments showcase DN Capital's knack for identifying and supporting companies that can scale globally. They have managed over $1 billion in assets and achieved numerous successful exits, including acquisitions by major corporations such as Apple (Shazam) and Oracle (Endeca)​. The firm is led by founders Nenad Marovac and Steve Schlenker, who bring deep entrepreneurial and financial expertise. DN Capital emphasizes a hands-on approach, providing portfolio companies with strategic guidance, business development opportunities, and extensive network connections. Their commitment to openness and integrity, combined with rigorous investment practices, makes them a strong partner for ambitious entrepreneurs